This study is designed to determine whether molecular detection of breast cancer cells in the peripheral blood of Stage IV breast cancer patients is a clinically relevant predictor of progression-free and overall survival. Stage IV breast cancer patients who have measurable breast cancer metastases and are initiating a regimen of systemic therapy are eligible for enrollment. Multi-marker real-time RT-PCR analysis will be performed on peripheral blood specimens from 92 breast cancer patients and 120 healthy volunteers. Peripheral blood specimens from breast cancer patients will be obtained at the time of study entry (prior to initiation of systemic therapy) and at serial time points during follow-up. Subjects will be followed longitudinally until death, although the study has been powered so that the primary objective can be addressed after 12 months of follow-up. Healthy volunteers will be asked to provide a blood sample at time of enrollment but will not be followed.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
224
Washington University School of Medicine
St Louis, Missouri, United States
Medical University of South Carolina
Charleston, South Carolina, United States
The prevalence of breast cancer cells in the peripheral blood
Specifically, it is predicted that 60% of subjects with Stage IV breast cancer will have evidence of breast cancer cells in the peripheral blood by multi-marker real-time RT-PCR analysis, and that these subjects will experience a significantly decreased progression-free and overall survival.
Time frame: 1 year
Evaluate the prognostic significance of molecular detection of breast cancer cells in peripheral blood after initiation of systemic therapy.
Specifically, we will determine if molecular detection of circulating breast cancer cells after the initiation of systemic therapy is associated with a significantly decreased progression-free and overall survival.
Time frame: Until patient death
Quantify baseline molecular marker expression levels in the peripheral blood of healthy volunteers
Determine if baseline molecular marker expression levels are dependent on patient age, race, and/or the presence of benign breast disease.
Time frame: Approximately 12 weeks
Compare molecular analyses to the results of the CellSeach assay
Time frame: Approximately 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.